A C Hesseling
Overview
Explore the profile of A C Hesseling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
2505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wademan D, Viljoen L, Jacobs S, Meyerson K, Nombewu Y, Busakwe L, et al.
Int J Tuberc Lung Dis
. 2023 Jun;
27(7):543-550.
PMID: 37353869
Multidrug-resistant TB (MDR-TB) treatment for children frequently includes unpalatable drugs with low overall acceptability. This can negatively impact children and their caregivers´ treatment experiences and is an important contributor to...
12.
Singh K, Carvalho A, Centis R, D Ambrosio L, Migliori G, Mpagama S, et al.
Int J Tuberc Lung Dis
. 2023 Jun;
27(7):506-519.
PMID: 37353868
Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE....
13.
Nightingale R, Carlin F, Meghji J, McMullen K, Evans D, van der Zalm M, et al.
Int J Tuberc Lung Dis
. 2023 Apr;
27(4):248-283.
PMID: 37035971
TB affects around 10.6 million people each year and there are now around 155 million TB survivors. TB and its treatments can lead to permanently impaired health and wellbeing. In...
14.
Taneja R, Nahata M, Scarim J, Pande P, Scarim A, Hoddinott G, et al.
Int J Tuberc Lung Dis
. 2023 Mar;
27(3):189-194.
PMID: 36855042
Bedaquiline (BDQ) tablets are indicated as part of a combination regimen for the treatment of multidrug-resistant TB in adults, adolescents and children. A dispersible tablet formulation is now approved but...
15.
Taneja R, Nahata M, Scarim J, Pande P, Scarim A, Hoddinott G, et al.
Int J Tuberc Lung Dis
. 2023 Feb;
27(1):13-18.
PMID: 36853133
Delamanid (DLM) tablets are recommended for the treatment of rifampicin-resistant TB. However, no liquid or dispersible tablet formulation of DLM is currently commercially available for patients with challenges ingesting these...
16.
Taneja R, Nahata M, Scarim J, Pande P, Scarim A, Hoddinott G, et al.
Int J Tuberc Lung Dis
. 2023 Feb;
27(2):106-112.
PMID: 36853102
BACKGROUND: Clofazimine (CFZ) is routinely used worldwide for the treatment of leprosy and TB. However, no liquid or dispersible tablet formulations of CFZ are currently available commercially for patients with...
17.
Gomes I, Garg T, Churchyard G, Gupta A, Hesseling A, Swindells S, et al.
Int J Tuberc Lung Dis
. 2023 Feb;
27(2):154-156.
PMID: 36853100
No abstract available.
18.
Anthony M, Hoddinott G, van Niekerk M, Mtshabe A, Pienaar A, Dewandel I, et al.
Public Health Action
. 2022 Dec;
12(4):201-205.
PMID: 36561904
Background: There is a lack of holistic health-related quality of life (HRQoL) measures for young children with respiratory disease, especially in low- and middle-income countries (LMICs). We aimed to understand...
19.
Baloyi D, Anthony M, Meyerson K, Mazibuko S, Wademan D, Viljoen L, et al.
Public Health Action
. 2022 Dec;
12(4):159-164.
PMID: 36561901
Background: South Africa has one the highest TB and HIV burdens globally. TB preventive therapy (TPT) reduces the risk of TB disease and TB-related mortality in adults and children living...
20.
Taneja R, Nahata M, Scarim J, Pande P, Scarim A, Hoddinott G, et al.
Int J Tuberc Lung Dis
. 2022 Nov;
26(12):1112-1117.
PMID: 36447311
Pretomanid (PMD) tablets are indicated as part of a combination regimen for the treatment of adults with pulmonary extensively drug-resistant, treatment-intolerant or non-responsive multidrug-resistant TB. No commercial liquid formulation is...